GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Asarina Pharma AB (STU:APS) » Definitions » PS Ratio

Asarina Pharma AB (STU:APS) PS Ratio : (As of Jun. 08, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Asarina Pharma AB PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Asarina Pharma AB's share price is €0.0676. Asarina Pharma AB's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €0.00. Hence, Asarina Pharma AB's PS Ratio for today is .

The historical rank and industry rank for Asarina Pharma AB's PS Ratio or its related term are showing as below:

STU:APS's PS Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 9.53
* Ranked among companies with meaningful PS Ratio only.

Asarina Pharma AB's Revenue per Sharefor the three months ended in Dec. 2023 was €0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €0.00.

Back to Basics: PS Ratio


Asarina Pharma AB PS Ratio Historical Data

The historical data trend for Asarina Pharma AB's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Asarina Pharma AB PS Ratio Chart

Asarina Pharma AB Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Get a 7-Day Free Trial - - - - -

Asarina Pharma AB Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Dec22 Jun23 Dec23
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Asarina Pharma AB's PS Ratio

For the Biotechnology subindustry, Asarina Pharma AB's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Asarina Pharma AB's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Asarina Pharma AB's PS Ratio distribution charts can be found below:

* The bar in red indicates where Asarina Pharma AB's PS Ratio falls into.



Asarina Pharma AB PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Asarina Pharma AB's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=0.0676/0
=

Asarina Pharma AB's Share Price of today is €0.0676.
Asarina Pharma AB's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Asarina Pharma AB  (STU:APS) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Asarina Pharma AB PS Ratio Related Terms

Thank you for viewing the detailed overview of Asarina Pharma AB's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Asarina Pharma AB (STU:APS) Business Description

Traded in Other Exchanges
Address
Fogdevreten 2, Karolinska Institutet Science Park, Solna, SWE, SE-171 65
Asarina Pharma AB is a Swedish biotech company developing Sepranolone for Allopregnanolone-related stress, compulsion and neurological disorders. Its product pipeline is built on over 40 years of research into llopregnanolone-related neurological disorders. With the new family of GAMSA compounds (GABA-A Modulating Steroid Antagonists) the company aims to deliver a new generation of efficacious and safe drugs for still widely untreated neuroendocrinological conditions.

Asarina Pharma AB (STU:APS) Headlines

No Headlines